Immunocytokines hold great potential as anticancer agents, as they use a specific antitumor antibody to deliver an immune-activating cytokine directly to the immunosuppressive tumor microenvironment (TME). We have developed a novel immunocytokine (KD033) composed of a fully human, high-affinity antiprogrammed death-ligand 1 (PD-L1) linked to the sushi-domain of the human IL-15/IL-15 receptor alpha (IL-15/IL-15Ra) complex. A murine PD-L1 cross-reactive KD033 surrogate (srKD033) and a nontargeting antibody (ntKD033) were also developed to investigate mechanism of action in murine tumor models. Efficacy analyses showed a robust antitumor effect of single-dose srKD033 in several diverse syngeneic murine tumor models. In a CT26 murine colon tumor model, single-dose srKD033 produced durable antitumor immunity as evidenced by resistance to subsequent tumor rechallenges. Mice responding to srKD033 treatment showed increased retention of PD-L1/IL-15 in the TME which likely facilitated prolonged IL-15–induced expansion of cytotoxic cells. Importantly, target-based PD-L1/IL-15 delivery via srKD033 was well-tolerated and induced significant antitumor activity in murine carcinoma models that are non- or minimally responsive to IL-15 or anti–PD-L1/PD-1 monotherapy.
CITATION STYLE
Martomo, S. A., Lu, D., Polonskaya, Z., Luna, X., Zhang, Z., Feldstein, S., … Patel, J. (2021). Single-dose anti–PD-L1/IL-15 Fusion Protein KD033 generates synergistic antitumor immunity with robust tumor-immune gene signatures and memory responses. Molecular Cancer Therapeutics, 20(2), 347–356. https://doi.org/10.1158/1535-7163.MCT-20-0457
Mendeley helps you to discover research relevant for your work.